Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Obesity is a chronic disease associated with many complications. Weight loss of 5–15% can improve many obesity-related complications. Despite the benefits of weight reduction, there are many challenges in losing weight and maintaining long-term weight loss. Pharmacotherapy can help people with obesity achieve and maintain their target weight loss, thereby reducing the risk of obesity-related complications. The prevalence of obesity in the USA has been increasing over the past few decades, and despite the availability of approved anti-obesity medications (AOMs), people with obesity may not be accessing or receiving treatment at levels consistent with the disease prevalence. Reasons for low levels of initiation and long-term use of AOMs may include reluctance of public health and medical organizations to recognize obesity as a disease, lack of reimbursement, provider inexperience, and misperceptions about the efficacy and safety of available treatments. This article aims to inform primary care providers about the mechanism of action of one class of AOMs, glucagon-like peptide 1 receptor agonists (GLP-1RAs), in weight loss and longer-term maintenance of weight loss, and the efficacy and safety of this treatment class. GLP-1RA therapy was initially developed to treat type 2 diabetes. Owing to their effectiveness in reducing body weight, once-daily subcutaneous administration of liraglutide 3.0 mg has been approved, and once-weekly subcutaneous administration of semaglutide 2.4 mg is being investigated in phase III trials, for obesity management. Considerations regarding adverse effects and contraindications for different drug classes are provided to help guide treatment decision-making when considering pharmacotherapy for weight management in patients with obesity. Obesity is a growing public health issue that increases the risk of developing heart disease, type 2 diabetes, and osteoarthritis. Weight loss can reduce the risk of developing these health problems but, despite this, levels of obesity remain high. Achieving and maintaining weight loss is challenging for many individuals. There is therefore a need for some patients to take medications to help them lose weight and prevent weight regain. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are a type of medication originally developed to treat type 2 diabetes, but are now being used for the treatment of obesity because they are effective at helping people to lose weight. One GLP-1RA, liraglutide, has been approved to treat obesity, and another, semaglutide, is in clinical trials. GLP-1RAs work by reducing the appetite and feelings of hunger, slowing the release of food from the stomach, and increasing feelings of fullness after eating. Most people can tolerate GLP-1RAs well. The most common side effects (nausea, vomiting, and diarrhea) are usually mild and occur in the first few weeks of treatment, reducing over time. Because of the difficulties many people face in maintaining weight loss, lifelong treatment may be needed. In clinical trials, GLP-1RAs were well tolerated and effective at helping people prevent weight regain, and may be a good option for long-term weight control and lowering patients’ chances of serious health problems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some effects, such as delayed gastric emptying, reverse quickly through restored antral motility,31 and central anorexigenic signaling in the hypothalamus may downregulate soon after GLP-1R stimulation ends.32”
From Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis (2025) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Within this axis, GLP-1 functions by acting on both the gut and the brain.391”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [391]
The cited source says what the claim attributes to it.
In the citing paper
“This activation holds the ability to modulate food consumption by reducing food intake and conveying signals of satiety to the brain.391”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [391]
In the citing paper
“acting peripherally and centrally to reduce appetite and promote satiety resulting in significant weight loss.9”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [9]
In the citing paper
“evidence suggests that CR is more effective than exercise alone at reducing body weight and fat mass [115, 122].”
From Targeting Intramyocellular Lipids to Improve Aging Muscle Function (2025) · cites this paper as [122]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“5 years in patients with type 2 diabetes who had either cardiovascular disease or risk factors for cardiovascular disease [60].”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“Rapid weight loss has been associated with gallbladder-related disorders including cholelithiasis and cholecystitis [67, 68], and these adverse events, while rare, have been observed more with GLP-1RAs compared with placebo in clinical trials [21, 38].”
BackgroundProspective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432 · cited 7×
“Given this pattern in weight loss following treatment with an AOM, anti-obesity therapy should be conceptualized as initiating weight loss followed by establishing a new weight plateau and assisting in maintaining this weight in the long term [9, 11].”
BackgroundInfluentialA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 3×
“…orlistat; placebo) 37%; 14%; 10% (Liraglutide 2.4/3.0 mg vs. orlistat) ‡ 5% weight loss: 52% vs. 29% (p\ 0.001) ‡ 10% weight loss: 26% vs. 16% (p = 0.04) Pi-Sunyer et al., 2015: placebo-controlled, double-blind, randomized, 56-week trial of liraglutide 3.0 mg QD in patients with BMI C 30 kg/m2 (or…”
BackgroundInfluential(2020) · PubMed · Cited by 2,642
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 2×
“However, the action of GLP-1 is glucose-dependent and blood glucose is only lowered by GLP-1 if concentrations are above fasting levels [40, 41].”
BackgroundChanges in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · cited 1×
“In addition, energy expenditure is decreased following diet-induced weight loss, with the implication that reduced food intake would need to be maintained in the long-term [12].”
BackgroundGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 5×
“These data suggest a potential for long-term benefit of liraglutide treatment in many patients, as weight loss of 5–15% has been shown to improve obesity-related complications including diabetes and cardiovascular disease risk factors [5, 9, 59].”
BackgroundInfluentialWing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828 · cited 1×
“These data suggest a potential for long-term benefit of liraglutide treatment in many patients, as weight loss of 5–15% has been shown to improve obesity-related complications including diabetes and cardiovascular disease risk factors [5, 9, 59].”
BackgroundLong-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449 · cited 7×
“Obesity is a chronic condition, characterized by changes in weight-regulating hormones that drive weight regain following weight loss [11], therefore it is no surprise that maintaining weight loss can prove just as challenging as losing weight in the first place.”
BackgroundInfluentialObesity and Cardiovascular Disease
Ortega, F. B., Lavie, C. J., & Blair, S. N. (2016) · Circulation Research · doi:10.1161/circresaha.115.306883 · Cited by 1,202
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 1×
“…received counseling on lifestyle modification (Liraglutide 3.0 mg; placebo) 63%; 27% (p\ 0.001) (Liraglutide 3.0 mg; placebo) 33%; 11% (p\ 0.001) NR Davies et al., 2015: placebo-controlled, randomized, double-blind, parallel-group 56-week trial of liraglutide 1.8 and 3.0 mg QD in patients…”
InfluentialAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 3×
“…maintenance at 2 years Liraglutide GLP-1RA Reduces appetite and food cravings [21] Increases satiety Alters food preference and reward pathways [21] Astrup et al., 2009; Astrup et al., 2012: placebo-controlled, randomized, 20-week trial for liraglutide (1.2, 1.8, 2.4, and 3.0 mg QD) with…”
BackgroundInfluentialGadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064 · cited 1×
“…15/92 mg vs. placebo, both p\ 0.0001) (PT 3.75/ 23 mg; PT 15/92 mg; placebo) 19%; 47%; 3% (PT 3.75/ 23 mg/15/ 92 mg vs. placebo, both p\ 0.0001) NR Gadde et al., 2011; Garvey et al., 2012: placebo-controlled, double-blind, randomized, 108-week trial of PT (7.5/ 46 mg or 15/92 mg) QD in patients…”
InfluentialGreenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036 · cited 1×
“…weight loss maintenance at 2 years Naltrexonebupropion Naltrexone: opioid antagonist Bupropion: aminoketone antidepressant [62] Suppresses appetite Greenway et al., 2010: placebo-controlled, double-blind, randomized, 56-week trial of naltrexone-bupropion (NB16 and NB32b) BID in patients with BMI…”
BackgroundThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 3×
“GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neuropeptide Y (NPY) and agouti-related peptide (AgRP) to increase measures of satiety and decrease hunger [32].”
BackgroundIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · cited 3×
“1 Overview of the actions of GLP-1 in the central nervous system [27, 29, 32, 41].”
BackgroundMagkos, F., Fraterrigo, G., Yoshino, J., Luecking, C., Kirbach, K., Kelly, S. C., de las Fuentes, L., He, S., Okunade, A. L., Patterson, B. W., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.005 · Cited by 886 · cited 1×
“Even a modest weight loss of 5% has been shown to improve cardiometabolic risk factors, including reduced systolic blood pressure and plasma triglyceride concentration, and increased multi-organ insulin sensitivity and b-cell function [6].”
BackgroundMaintenance of Lost Weight and Long-Term Management of Obesity
Hall, K. D., & Kahan, S. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.012 · Cited by 876 · cited 1×
“Such an environment encompasses the interrelated issues of exposure to high-density, highly caloric foods, the relatively low cost of these foods, and physical environments that limit the scope of physical activity [13].”
BackgroundLong-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876 · cited 1×
“This suggests that, to maintain weight loss, treatment for obesity should be considered chronic (as in the case of hypertension), rather than as a short course of treatment associated with acute illnesses [9, 55].”
Backgroundle Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850 · cited 15×
“Given this pattern in weight loss following treatment with an AOM, anti-obesity therapy should be conceptualized as initiating weight loss followed by establishing a new weight plateau and assisting in maintaining this weight in the long term [9, 11].”
BackgroundInfluentialon behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814 · cited 1×
“In a phase II study, gastrointestinal side effects were most common during semaglutide dose escalation but weight loss persisted beyond these events and continued through the 52-week trial period [51].”
Backgroundon behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 5×
“…GLP-1RA Reduces appetite and food cravings [21] Increases satiety Alters food preference and reward pathways [21] Astrup et al., 2009; Astrup et al., 2012: placebo-controlled, randomized, 20-week trial for liraglutide (1.2, 1.8, 2.4, and 3.0 mg QD) with open-label comparator…”
BackgroundResultInfluentialApovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720 · cited 1×
“…NB32; placebo) 39%; 48%; 16% (NB16/NB32 vs. placebo, both p\ 0.0001) (NB16; NB32; placebo) 20%; 25%; 7% (NB16/ NB32 vs. placebo, both p\ 0.0001) NR Apovian et al., 2013: placebo-controlled, double-blind, randomized, 56-week trial of naltrexone-bupropion (NB32) BID in patients with BMI C 30 (or C…”
InfluentialGarvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711 · cited 1×
“…maintenance at 2 years Phenterminetopiramate Phentermine: sympathomimetic amine anorectic [64] Topiramate: antiepileptic drug Suppresses appetite Allison et al., 2012: placebo-controlled, randomized, 56-week trial of PT (3.75/ 23 mg or 15/92 mg) QD added to a reduced-energy diet in patients…”
BackgroundInfluentialBlundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693 · cited 2×
“Since GLP-1RA therapy has been shown to reduce preference for fatty foods [26], GLP-1RA therapy might be preferred for patients who would find it difficult to avoid fatty foods under normal circumstances.”
BackgroundFidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 561 · cited 1×
“Treatment with an AOM often follows a pattern of initial weight loss that tends to level out, or ‘‘plateau’’, after a period of time on treatment [54, 56, 57].”
BackgroundFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558 · cited 1×
“…diet, increased physical activity, and behavioral modification advice (NB32; placebo) 51%; 17% (p\ 0.001) (NB32; placebo) 28%; 6% (p\ 0.001) NR Wadden et al., 2011: placebo-controlled, double-blind, randomized, 56-week trial of naltrexone-bupropion (NB32) QD and BMOD in patients with BMI C 30…”
BackgroundInfluentialvan Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 2×
“Studies investigating the mechanism of action of GLP-1RA therapy for causing weight loss provide evidence that GLP-1RA treatment is associated with reductions in appetite and hunger, lower preference for energy-dense foods, alteration in food reward pathways, decrease in food cravings, and improvement in eating contro…”
BackgroundHollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501 · cited 1×
“…30 (or C 27 with controlled hypertension and/or dyslipidemia) to 45 kg/m2 (NB32; placebo) 66%; 43% (p\ 0.001) (NB32; placebo) 42%; 20% (p\ 0.001) NR Hollander et al., 2013: placebo-controlled, double-blind, randomized, 56-week trial of naltrexone-bupropion (NB32) QD in patients with BMI C 27 and B…”
InfluentialRössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476 · cited 1×
“…orlistat 120 mg vs. placebo: p = 0.02) ‡ 10% weight loss: 15%; 19%; 7% (Orlistat 60 mg vs. placebo: p = 0.008; orlistat 120 mg vs. placebo: p = 0.001) Rössner et al., 2000: placebo-controlled, double-blind, randomized, 2-year trial of orlistat (60 and 120 mg) TID in patients with BMI 28–43…”
InfluentialFriedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14280 · Cited by 427
Cardiovascular risk and obesity
Cercato, C., & Fonseca, F. A. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0468-0 · Cited by 395
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394
Orlistat in the long-term treatment of obesity in primary care settings.
Hauptman, J. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.2.160 · Cited by 367 · cited 1×
“…of patients achieving weight loss maintenance at 2 years Orlistat Reversible inhibitor of gastrointestinal lipases [65] Inhibits fat absorption Hauptman et al., 2000: placebo-controlled, double-blind, randomized, 2-year trial of orlistat (60 and 120 mg TID) in patients with BMI 30–44…”
BackgroundGough, S. C. L., Bode, B., Woo, V., Rodbard, H. W., Linjawi, S., Poulsen, P., Damgaard, L. H., & Buse, J. B. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70174-3 · Cited by 366
Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study
Kaplan, L. M., Golden, A., Jinnett, K., Kolotkin, R. L., Kyle, T. K., Look, M., Nadglowski, J., O'Neil, P. M., Parry, T., Tomaszewski, K. J., et al. (2018) · Obesity · doi:10.1002/oby.22054 · Cited by 312 · cited 2×
“Nearly all other interventions listed (including improved eating habits, exercise tracking, counseling or lifestyle modification, and visiting a dietitian) were perceived to be more effective than AOMs [16], indicating a lack of knowledge about the potential benefits of pharmacotherapy.”
BackgroundAroda, V. R., Ahmann, A., Cariou, B., Chow, F., Davies, M. J., Jódar, E., Mehta, R., Woo, V., & Lingvay, I. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.12.001 · Cited by 296
Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., et al. (2020) · Obesity · doi:10.1002/oby.22794 · Cited by 288
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287 · cited 1×
“However, the action of GLP-1 is glucose-dependent and blood glucose is only lowered by GLP-1 if concentrations are above fasting levels [40, 41].”
BackgroundFarr, O. M., Sofopoulos, M., Tsoukas, M. A., Dincer, F., Thakkar, B., Sahin-Efe, A., Filippaios, A., Bowers, J., Srnka, A., Gavrieli, A., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3874-y · Cited by 287 · cited 2×
“1 Overview of the actions of GLP-1 in the central nervous system [27, 29, 32, 41].”
BackgroundHjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13120 · Cited by 245 · cited 1×
“In pharmacology trials, GLP-1RA treatment has been shown to delay gastric emptying within the first postprandial hour [25, 28], although overall gastric emptying did not appear to be affected [28], suggesting additional mechanisms of action in GLP-1RA-mediated weight loss.”
BackgroundCefalu, W. T., Bray, G. A., Home, P. D., Garvey, W. T., Klein, S., Pi-Sunyer, F. X., Hu, F. B., Raz, I., Van Gaal, L., Wolfe, B. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1081 · Cited by 243
Gallstones in obesity and weight loss
Erlinger, S. (2000) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200012120-00015 · Cited by 215 · cited 1×
“Rapid weight loss has been associated with gallbladder-related disorders including cholelithiasis and cholecystitis [67, 68], and these adverse events, while rare, have been observed more with GLP-1RAs compared with placebo in clinical trials [21, 38].”
Backgroundon behalf of the NN8022-1807 Investigators, Lean, M. E. J., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., Van Gaal, L., & Astrup, A. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.149 · Cited by 210 · cited 1×
“0 mg, in which nausea was the most frequent adverse event, showed that greater weight loss was associated with transient nausea and vomiting in participants with obesity but without diabetes [50].”
BackgroundWadden, T. A., Tronieri, J. S., Sugimoto, D., Lund, M. T., Auerbach, P., Jensen, C., & Rubino, D. (2020) · Obesity · doi:10.1002/oby.22726 · Cited by 200 · cited 1×
“…received diet and exercise counseling (Liraglutide 3.0 mg; placebo)a 51%; 22% (p\ 0.0001) (Liraglutide 3.0 mg; placebo)a 26%; 6% (p\ 0.0001) NR Wadden et al., 2020b: placebo-controlled, double-blind, randomized, 56-week trial of liraglutide 3.0 mg QD plus IBT in patients with BMI C 30…”
InfluentialCentral nervous system regulation of eating: Insights from human brain imaging
Farr, O. M., Li, C.-S. R., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.002 · Cited by 191
Garvey, W. T., Birkenfeld, A. L., Dicker, D., Mingrone, G., Pedersen, S. D., Satylganova, A., Skovgaard, D., Sugimoto, D., Jensen, C., & Mosenzon, O. (2020) · Diabetes Care · doi:10.2337/dc19-1745 · Cited by 186 · cited 2×
“…mg QD plus IBT in patients with BMI C 30 kg/m2 (Liraglutide 3.0 mg; placebo) 62%; 34% (p = 0.0003) (Liraglutide 3.0 mg; placebo) 31%; 20% (p = 0.0469) NR Garvey et al., 2020: placebo-controlled, double-blind, randomized, 56-week trial of liraglutide 3.0 mg QD plus IBT in patients with BMI of C 27…”
BackgroundInfluentialKadouh, H., Chedid, V., Halawi, H., Burton, D. D., Clark, M. M., Khemani, D., Vella, A., Acosta, A., & Camilleri, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz140 · Cited by 166
van Bloemendaal, L., Veltman, D. J., ten Kulve, J. S., Groot, P. F. C., Ruhé, H. G., Barkhof, F., Sloan, J. H., Diamant, M., & Ijzerman, R. G. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12506 · Cited by 151 · cited 1×
“Studies investigating the mechanism of action of GLP-1RA therapy for causing weight loss provide evidence that GLP-1RA treatment is associated with reductions in appetite and hunger, lower preference for energy-dense foods, alteration in food reward pathways, decrease in food cravings, and improvement in eating contro…”
BackgroundNylander, M., Frøssing, S., Clausen, H. V., Kistorp, C., Faber, J., & Skouby, S. O. (2017) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2017.03.023 · Cited by 139 · cited 2×
“If other health problems such as prediabetes or polycystic ovary syndrome (PCOS) are present, GLP-1RA therapy might be preferred over other treatment options.”
BackgroundThethi, T. K., Pratley, R., & Meier, J. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14054 · Cited by 134
Thomas, C. E., Mauer, E. A., Shukla, A. P., Rathi, S., & Aronne, L. J. (2016) · Obesity · doi:10.1002/oby.21533 · Cited by 124 · cited 1×
“However, despite their availability, adoption of medications for the management of obesity remains low [14, 15].”
BackgroundKang, J. G., Park, C. ‐., Kang, J. H., Park, Y. ‐., & Park, S. W. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01242.x · Cited by 120 · cited 4×
“Percentage of patients achieving weight loss maintenance at 2 years Phenterminetopiramate Phentermine: sympathomimetic amine anorectic [64] Topiramate: antiepileptic drug Suppresses appetite Allison et al., 2012: placebo-controlled, randomized, 56-week trial of PT (3.75/ 23 mg or 15/92 mg) QD added to a reduced-energy…”
BackgroundInfluentialIepsen, E. W., Lundgren, J., Dirksen, C., Jensen, J.-E., Pedersen, O., Hansen, T., Madsbad, S., Holst, J. J., & Torekov, S. S. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.177 · Cited by 118 · cited 2×
“One of the mechanisms thought to be responsible for weight regain or plateau is a reduction in circulating levels of leptin after initial weight loss [11, 58].”
BackgroundHorowitz, M., Aroda, V. R., Han, J., Hardy, E., & Rayner, C. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12872 · Cited by 79 · cited 2×
“However, patients with type 2 diabetes were included in these trials [52, 53], which could have contributed to the observed differences.”
BackgroundSimon, R., & Lahiri, S. W. (2018) · Endocrine Practice · doi:10.4158/ep-2017-0221 · Cited by 59 · cited 1×
“However, despite their availability, adoption of medications for the management of obesity remains low [14, 15].”
BackgroundManagement of gallstones and gallbladder disease in patients undergoing gastric bypass
Quesada, B. M. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i17.2075 · Cited by 50 · cited 1×
“Rapid weight loss has been associated with gallbladder-related disorders including cholelithiasis and cholecystitis [67, 68], and these adverse events, while rare, have been observed more with GLP-1RAs compared with placebo in clinical trials [21, 38].”
BackgroundChanges in Energy Expenditure Resulting from Altered Body Weight
(1995) · New England Journal of Medicine · doi:10.1056/nejm199508103330628 · Cited by 50
Pratley, R. E., Kang, J., Trautmann, M. E., Hompesch, M., Han, O., Stewart, J., Sorli, C. H., Jacob, S., & Yoon, K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13824 · Cited by 49
Pharmacotherapy for obesity: What you need to know
Bersoux, S., Byun, T. H., Chaliki, S. S., & Poole, K. G. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.16094 · Cited by 46 · cited 3×
“Anti-obesity medication Type of agent/ mechanism of action [23] Trial information Percentage of patients achieving categorial weight loss at 1 year”
BackgroundBaum, C., Andino, K., Wittbrodt, E., Stewart, S., Szymanski, K., & Turpin, R. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0264-0 · Cited by 42
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
Waldrop, G. E., Zhong, J., Peters, M. C., Goud, A., Chen, Y., Davis, S. N., Mukherjee, B., & Rajagopalan, S. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.08.018 · Cited by 41 · cited 14×
“Most people can tolerate GLP-1RAs well.”
BackgroundInfluentialCoveleskie, K., Kilpatrick, L. A., Gupta, A., Stains, J., Connolly, L., Labus, J. S., Sanmiguel, C., & Mayer, E. A. (2017) · Obesity Science & Practice · doi:10.1002/osp4.124 · Cited by 40 · cited 1×
“The reduced feelings of hunger were associated with an increase in functional connectivity of the nucleus tract solitaries with the hypothalamus and thalamus [31].”
BackgroundDesign, findings and implications of the liraglutide Phase III clinical trial program
Bode, B. W. (2011) · Clinical Investigation · doi:10.4155/cli.11.166 · Cited by 11
Trautmann, M. E., Han, J., & Ruggles, J. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.039 · Cited by 11 · cited 2×
“However, patients with type 2 diabetes were included in these trials [52, 53], which could have contributed to the observed differences.”
BackgroundWadden, T. A., Bailey, T. S., Billings, L. K., Frías, J. P., Koroleva, A., Gollan, R., O'Neil, P. M., Rubino, D., Skovgaard, D., Wallenstein, S. O. R., et al. (2021) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/s-0041-1735669 · Cited by 3
Friedrichsen, M. H., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. C. (2020) · Publons reviews and discussion · doi:10.1111/dom.14280/v2/response1 · Cited by 1
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff, A. M., & Kushner, R. F. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-014919 · Cited by 158
Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148
Sherwin, M., Hamburger, J., Katz, D., & DeMaria, S. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02549-5 · Cited by 132
“Glucagon-like peptide-1 receptor agonists are an increasingly popular class of drugs for diabetes mellitus and weight loss management.(3,7) While they are effective in this regard, they induce delayed gastric emptying, which may increase the likelihood that patients do not have an empty stomach when they present for s…”
BackgroundWang, L., Berger, N. A., Kaelber, D. C., & Xu, R. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.04.029 · Cited by 130
Metadata
- Authors
- Ard, J., Fitch, A., Fruh, S., & Herman, L.
- Affiliations
- Atrium Health Wake Forest Baptist (US)
- Harvard University (US)
- University of South Alabama (US)
- University of Lynchburg (US)
- Corresponding author
- Ard, Jamy
- Venue
- Advances in Therapy
- Published
- 2021-05-11
- Volume
- 38
- Issue
- 6
- Pages
- 2821-2839
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- PMC
- PMC8189979
- OpenAlex
- W3163721607
- Cited by
- 297
- References
- 73
- Citations by year
- 2026: 46 · 2025: 99 · 2024: 84 · 2023: 47 · 2022: 19 · 2021: 2
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Advances in Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk Inc
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, obesity pharmacotherapy, weight loss, weight maintenance, liraglutide, semaglutide, appetite suppression, anti-obesity drugs, obesity as a disease, barriers to treatment, obesity complications, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Diabetes Mellitus, Type 2, Pharmaceutical Preparations, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Fig. 1 Overview of the actions of GLP-1 in the central nervous system [27, 29, 32, 41]. AgRP agouti-related peptide, CART cocaine- and amphetamine-regulated transcript, GLP-1RA glucagon-like peptide 1 receptor agonist, NPY neuropeptide Y, POMC proopiomelanocortin](https://figures.cochat.ai/paper-figures/cfc07b75f2124c5894ea2d0391dfd6f5/weight-loss-and-maintenance-related-to-the-mechanism-of-action-of-glucagon-like-figure-1.jpg)